Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Posted by Kyle Jackson on May 7th, 2026

Embecta (NASDAQ:EMBC – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.550-1.75 for the period, compared to the consensus earnings per share estimate of 2.820. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. Mizuho dropped their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, BTIG Research downgraded shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday. Four investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $15.00.

Check Out Our Latest Analysis on EMBC

Embecta Stock Up 1.3%

Shares of EMBC stock traded up $0.05 during trading hours on Thursday, hitting $3.61. 4,699,167 shares of the company’s stock traded hands, compared to its average volume of 1,106,736. The stock’s 50 day simple moving average is $8.98 and its 200 day simple moving average is $11.13. The stock has a market cap of $213.49 million, a PE ratio of 1.90 and a beta of 1.09. Embecta has a 12 month low of $3.45 and a 12 month high of $15.55.

Embecta (NASDAQ:EMBC – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The business had revenue of $221.80 million for the quarter, compared to the consensus estimate of $232.42 million. During the same period in the previous year, the business posted $0.70 EPS. Embecta’s revenue was down 14.4% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, equities research analysts expect that Embecta will post 1.65 EPS for the current fiscal year.

Embecta Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, May 28th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, May 28th. Embecta’s dividend payout ratio (DPR) is currently 2.11%.

Hedge Funds Weigh In On Embecta

Hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in Embecta by 49.3% in the fourth quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock valued at $196,000 after purchasing an additional 5,460 shares in the last quarter. State of Tennessee Department of Treasury increased its stake in Embecta by 23.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock valued at $633,000 after purchasing an additional 10,263 shares in the last quarter. Mackenzie Financial Corp increased its stake in Embecta by 34.0% in the fourth quarter. Mackenzie Financial Corp now owns 135,085 shares of the company’s stock valued at $1,627,000 after purchasing an additional 34,240 shares in the last quarter. XTX Topco Ltd bought a new stake in Embecta in the fourth quarter valued at $234,000. Finally, VARCOV Co. bought a new stake in Embecta in the fourth quarter valued at $179,000. Institutional investors own 93.83% of the company’s stock.

About Embecta

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.